Note: This webinar took place on 29 October 2018. You can find a video recording and the presentations used during the webinar below. Webinar introduction Amongst other profound changes and consequences, the EU’s new General Data Protection Regulation also influences how clinical trials can recruit and be organised. Two legal experts discuss these consequences and what they…Read more
Clinical Development and Trials
Note: This webinar took place on 28 June 2018. You can find a video recording and the presentations used during the webinar below. Webinar introduction Community advisory boards (CAB) are an effective and increasingly widely used structure to create neutral and scientifically framed platforms for all stakeholders involved in medicine research and development to interact on equal…Read more
Note: This webinar took place on 8 February 2018. You can find a video recording and the presentations used during the webinar below. Webinar introduction A patient registry is an organised system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition,…Read more
Novo-Nordisk, a pharmaceutical company, does user research with patients to enhance understanding of patients and to develop products that meet users’ needs.
Involvement of the foundation ‘Children with SMA’ (spinal muscular atrophy) with an academic institution in Ukraine to design a pilot clinical trial addressing issues in SMA clinical trials.
Involvement of European Tuberous Sclerosis Complex Patient Organisations (E-TSC) establishing an European registry of patients living with Tuberous sclerosis complex (TSC) to address some gaps in understanding the clinical course of TSC and the therapeutic outcomes.
Novartis Advisory Board meets with six National Psoriasis Patient Organisations to address patient relevant endpoints in psoriasis clinical trials.
Collaboration between patients and a Psoriasis Association representative with the ‘Focus on the Patient’ division from GSK, to understand the impact of psoriasis on the lives of patients, their own views, and future clinical study endpoints.
Patients were asked by GlaxoSmithKline staff members to review a draft plain language summary from a completed Phase III study. The patients provided valuable feedback about the wording, structure, and content of the plain language summary.
Collaboration between the International Alliance of Patient’s Organisations and local patient organisations with pharmaceutical company Novo Nordisk A/S to facilitate dialogue between them and develop learnings for future use.